Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine.

Infection and immunity - 1 Nov 2003

Ugalde Juan Esteban, Comerci Diego José, Leguizamón M Susana, Ugalde Rodolfo Augusto

Abstract excerpt

Brucella abortus S19 is the vaccine most frequently used against bovine brucellosis. Although it induces good protection levels, it cannot be administered to pregnant cattle, revaccination is not advised due to interference in the discrimination between infected and vaccinated animals during immune-screening procedures, and the vaccine is virulent for humans. Due to these reasons, there is a continuous search for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bacterial
Share to Brucella abortus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-gamma

Share to Interleukin-4

Share to Lymphocyte Activation

Share to Mice, Inbred BALB C

Share to O Antigens

Share to Phosphoglucomutase

Source

Open in PubMed Open full text

Identifiers

PMID: 14573645
DOI: 10.1128/IAI.71.11.6264-6269.2003
PMCID: PMC219583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine.PMID 14573645Read ↗

The Brucella melitensis M5-90 phosphoglucomutase (PGM) mutant is attenuated and confers protection against wild-type challenge in BALB/c mice.Semantic proximity Read ↗

Intermediate rough Brucella abortus S19Δper mutant is DIVA enable, safe to pregnant guinea pigs and confers protection to mice.Semantic proximity Read ↗

Brucella melitensis M5-90Δbp26 as a potential live vaccine that allows for the distinction between natural infection and immunizationSemantic proximity Read ↗

Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections.Semantic proximity Read ↗

The<i>Brucella abortus</i>Phosphoglycerate Kinase Mutant Is Highly Attenuated and Induces Protection Superior to That of Vaccine Strain 19 in Immunocompromised and Immunocompetent MiceSemantic proximity Read ↗

An investigation of novel DNA based vaccines for protection against brucellosisSemantic proximity Read ↗

Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export.Semantic proximity Read ↗

Rough brucella strain RM57 is attenuated and confers protection against Brucella melitensis.Semantic proximity Read ↗

Characteristics of Brucella abortus vaccine strain A19 reveals its potential mechanism of attenuated virulence.Semantic proximity Read ↗

Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines.Semantic proximity Read ↗

Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.Semantic proximity Read ↗

Antigenic, immunologic and genetic characterization of rough strains B. abortus RB51, B. melitensis B115 and B. melitensis B18.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.